SE9700136D0 - New formulation - Google Patents

New formulation

Info

Publication number
SE9700136D0
SE9700136D0 SE9700136A SE9700136A SE9700136D0 SE 9700136 D0 SE9700136 D0 SE 9700136D0 SE 9700136 A SE9700136 A SE 9700136A SE 9700136 A SE9700136 A SE 9700136A SE 9700136 D0 SE9700136 D0 SE 9700136D0
Authority
SE
Sweden
Prior art keywords
new formulation
formulation
useful
treatment
dry powder
Prior art date
Application number
SE9700136A
Other languages
English (en)
Swedish (sv)
Inventor
Jan Trofast
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9700136A priority Critical patent/SE9700136D0/xx
Publication of SE9700136D0 publication Critical patent/SE9700136D0/xx
Priority to US09/005,100 priority patent/US5980949A/en
Priority to TR1999/01689T priority patent/TR199901689T2/xx
Priority to CNB988019019A priority patent/CN1195507C/zh
Priority to AT98901619T priority patent/ATE263552T1/de
Priority to UA99074045A priority patent/UA57765C2/uk
Priority to DE69823045T priority patent/DE69823045T2/de
Priority to IL13083998A priority patent/IL130839A/en
Priority to KR10-1999-7006415A priority patent/KR100528415B1/ko
Priority to RU99118586/14A priority patent/RU2180562C2/ru
Priority to EEP199900293A priority patent/EE03950B1/xx
Priority to PCT/SE1998/000041 priority patent/WO1998031353A1/fr
Priority to SK960-99A priority patent/SK283943B6/sk
Priority to PL98334526A priority patent/PL189551B1/pl
Priority to ES98901619T priority patent/ES2217535T3/es
Priority to AU57860/98A priority patent/AU728768B2/en
Priority to NZ336595A priority patent/NZ336595A/xx
Priority to BR9806893-8A priority patent/BR9806893A/pt
Priority to NL1008020A priority patent/NL1008020C2/nl
Priority to JP53421998A priority patent/JP2001509812A/ja
Priority to HU0000755A priority patent/HUP0000755A3/hu
Priority to CA002277891A priority patent/CA2277891C/fr
Priority to CZ19992558A priority patent/CZ295665B6/cs
Priority to EP98901619A priority patent/EP1014955B1/fr
Priority to GR980100023A priority patent/GR980100023A/el
Priority to BE9800030A priority patent/BE1012009A5/fr
Priority to IE980026A priority patent/IE980026A1/en
Priority to ES009800080A priority patent/ES2149083B1/es
Priority to FR9800460A priority patent/FR2759905B1/fr
Priority to IDW990662A priority patent/ID21929A/id
Priority to IS5107A priority patent/IS2072B/is
Priority to NO993540A priority patent/NO993540L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
SE9700136A 1994-10-03 1997-01-20 New formulation SE9700136D0 (sv)

Priority Applications (32)

Application Number Priority Date Filing Date Title
SE9700136A SE9700136D0 (sv) 1997-01-20 1997-01-20 New formulation
US09/005,100 US5980949A (en) 1994-10-03 1998-01-09 Formulation for inhalation
EP98901619A EP1014955B1 (fr) 1997-01-20 1998-01-13 Nouvelle formulation pour inhalation ayant une densite en vrac de 0,28 a 0,38 g/ml et contenant du sulfate de terbutaline, procede de preparation et utilisation de cette formulation
ES98901619T ES2217535T3 (es) 1997-01-20 1998-01-13 Nueva formulacion para inhalacion, con una densidad aparente de 0,28 a 0,38 g/ml determinada por colada, que comprende sulfato de terbutalina, un procedimiento para preparar la formulacion, y el uso de la misma.
BR9806893-8A BR9806893A (pt) 1997-01-20 1998-01-13 Nova formulação para inalação; apresentando densidade volumétrica, quando derramada, de 0,20 a 038 g/ml, compreendendo sulfato de terbutalina, processo para preparação da formulação e uso da mesma
AT98901619T ATE263552T1 (de) 1997-01-20 1998-01-13 Neuartige formulierung zur inhalation mit einer bulkdichte zwischen 0.28 und 0.38 g/ml, mit terbutalinsulphat, verfahren zur herstellung der formulierung sowie anwendung derselben
UA99074045A UA57765C2 (uk) 1997-01-20 1998-01-13 Суха порошкова композиція, яка містить сульфат тербуталіну, спосіб її виготовлення та спосіб лікування
DE69823045T DE69823045T2 (de) 1997-01-20 1998-01-13 Neuartige formulierung zur inhalation mit einer bulkdichte zwischen 0.28 und 0.38 g/ml, mit terbutalinsulphat, verfahren zur herstellung der formulierung sowie anwendung derselben
IL13083998A IL130839A (en) 1997-01-20 1998-01-13 Inhalation preparation with an ejaculation density of between 0.28 and 0.38 g / ml containing trabutlin sulfate Process for the preparation and use of the preparation
KR10-1999-7006415A KR100528415B1 (ko) 1997-01-20 1998-01-13 0.28 내지 0.38 ｇ/㎖의 유동 벌크 밀도를 갖는 테르부탈린 술페이트 함유 신규 흡입 제제, 그의 제조 방법 및 그의 용도
RU99118586/14A RU2180562C2 (ru) 1997-01-20 1998-01-13 Препарат для ингаляции, имеющий насыпную объемную плотность 0,28 - 0,38 г/мл, содержащий тербуталина сульфат, способ его получения и его применение
EEP199900293A EE03950B1 (et) 1997-01-20 1998-01-13 Inhaleeritav terbutaliinsulfaati sisaldav ravimvorm puistetihedusega 0,28 kuni 0,38 g/ml, meetod selle valmistamiseks ja kasutamine
PCT/SE1998/000041 WO1998031353A1 (fr) 1997-01-20 1998-01-13 Nouvelle formulation pour inhalation ayant une densite en vrac de 0,28 a 0,38 g/ml et contenant du sulfate de terbutaline, procede de preparation et utilisation de cette formulation
SK960-99A SK283943B6 (sk) 1997-01-20 1998-01-13 Inhalačná kompozícia, spôsob jej prípravy a jej použitie na prípravu liečiva
PL98334526A PL189551B1 (pl) 1997-01-20 1998-01-13 Sucha kompozycja proszkowa do inhalacji, sposób jej wytwarzania oraz zastosowanie tej kompozycji dowytwarzania leku
TR1999/01689T TR199901689T2 (xx) 1997-01-20 1998-01-13 Terb�talin s�lfat i�eren, yeni solunum form�lasyonu.
AU57860/98A AU728768B2 (en) 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising terbutaline sulphate, a process for preparing the formulation and the use thereof
NZ336595A NZ336595A (en) 1997-01-20 1998-01-13 Formulation for inhalation comprising finely divided terbutaline sulphate and a carrier (lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol or starch)
CNB988019019A CN1195507C (zh) 1997-01-20 1998-01-13 注入堆积密度为0.28～0.38g/ml的含有特布他林硫酸盐的吸入用新配方法、该配方的制备及其用途
NL1008020A NL1008020C2 (nl) 1997-01-20 1998-01-13 Nieuwe formulering voor inhalatie.
JP53421998A JP2001509812A (ja) 1997-01-20 1998-01-13 硫酸テルブタリンを含む０．２８から０．３８ｇ／ｍｌの流動かさ密度を有する吸入用新規製剤、その製剤を調製する方法およびその使用
HU0000755A HUP0000755A3 (en) 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of from 0,28 to 0,38 g/ml, comprising terbutaline sulphate, a process for preparing the formulation and the use thereof
CA002277891A CA2277891C (fr) 1997-01-20 1998-01-13 Nouvelle formulation pour inhalation ayant une densite en vrac de 0,28 a 0,38 g/ml et contenant du sulfate de terbutaline, procede de preparation et utilisation de cette formulation
CZ19992558A CZ295665B6 (cs) 1997-01-20 1998-01-13 Suchý práškový prostředek s obsahem terbutalinsulfátu, způsob jeho přípravy a léčivo s jeho obsahem
GR980100023A GR980100023A (el) 1997-01-20 1998-01-14 Νεα συνθεση για εισπνοη
BE9800030A BE1012009A5 (fr) 1997-01-20 1998-01-15 Nouvelle composition pour inhalation.
IE980026A IE980026A1 (en) 1997-01-20 1998-01-16 New formulation for inhalation
ES009800080A ES2149083B1 (es) 1997-01-20 1998-01-16 Nueva formulacion para inhalacion.
FR9800460A FR2759905B1 (fr) 1997-01-20 1998-01-16 Nouvelle composition pour inhalation
IDW990662A ID21929A (id) 1997-01-20 1998-01-30 Formulasi untuk inhalasi yang memiliki densitas ruah tertuang dari 0.28 sampai 0,38 g/ml, yang mengandung terbutalina sulfat, proses pembuatan dan penggunaan formulasi tersebut
IS5107A IS2072B (is) 1997-01-20 1999-07-06 Ný efnablanda til innöndunar sem er með lausþéttniflæði frá 0,28 til 0,38 g/ml, sem inniheldur terbútalínsúlfat, aðferð við að framleiða efnablöndunaog notkun hennar
NO993540A NO993540L (no) 1997-01-20 1999-07-19 Ny formulering for inhalering som har bulkdensitet ved helling fra 0,28 til 0,38 g/ml, omfattende tebutalinsulfat,en fremgangsmÕte for fremstilling av formuleringen og anvendelse derav

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9700136A SE9700136D0 (sv) 1997-01-20 1997-01-20 New formulation

Publications (1)

Publication Number Publication Date
SE9700136D0 true SE9700136D0 (sv) 1997-01-20

Family

ID=20405456

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9700136A SE9700136D0 (sv) 1994-10-03 1997-01-20 New formulation

Country Status (30)

Country Link
EP (1) EP1014955B1 (fr)
JP (1) JP2001509812A (fr)
KR (1) KR100528415B1 (fr)
CN (1) CN1195507C (fr)
AT (1) ATE263552T1 (fr)
AU (1) AU728768B2 (fr)
BE (1) BE1012009A5 (fr)
BR (1) BR9806893A (fr)
CA (1) CA2277891C (fr)
CZ (1) CZ295665B6 (fr)
DE (1) DE69823045T2 (fr)
EE (1) EE03950B1 (fr)
ES (2) ES2217535T3 (fr)
FR (1) FR2759905B1 (fr)
GR (1) GR980100023A (fr)
HU (1) HUP0000755A3 (fr)
ID (1) ID21929A (fr)
IE (1) IE980026A1 (fr)
IL (1) IL130839A (fr)
IS (1) IS2072B (fr)
NL (1) NL1008020C2 (fr)
NO (1) NO993540L (fr)
NZ (1) NZ336595A (fr)
PL (1) PL189551B1 (fr)
RU (1) RU2180562C2 (fr)
SE (1) SE9700136D0 (fr)
SK (1) SK283943B6 (fr)
TR (1) TR199901689T2 (fr)
UA (1) UA57765C2 (fr)
WO (1) WO1998031353A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI991582A1 (it) 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
JP2001151673A (ja) * 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
SE0200657D0 (sv) * 2002-03-04 2002-03-04 Astrazeneca Ab Novel Formulation
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
EP1599209B1 (fr) 2002-08-21 2011-08-17 Norton Healthcare Limited Compositions a inhaler
DE102007049931A1 (de) 2007-10-18 2009-04-23 Pharmatech Gmbh Vorrichtung und Verfahren zur kontinuierlichen Herstellung von sphärischen Pulveragglomeraten
EP2255807A1 (fr) 2009-05-26 2010-12-01 Sanofi-Aventis Procédé de traitement des troubles du sommeil utilisant la combinaison d'éplivanserine et zolpidem
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0072046B1 (fr) * 1981-07-24 1986-01-15 FISONS plc Médicaments pour inhalation, méthodes pour leur production et formulations pharmaceutiques les contenant
ATE17441T1 (de) * 1981-07-24 1986-02-15 Fisons Plc Inhalierbare arzneimittel, verfahren zu deren herstellung und pharmazeutische formulierungen diese enthaltend.
IL111080A (en) * 1993-10-01 1999-08-17 Astra Ab Method for treating a finely divided powder medicament
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination

Also Published As

Publication number Publication date
NZ336595A (en) 2001-01-26
HUP0000755A3 (en) 2001-03-28
CZ295665B6 (cs) 2005-09-14
CN1195507C (zh) 2005-04-06
BE1012009A5 (fr) 2000-04-04
CA2277891C (fr) 2006-08-29
TR199901689T2 (xx) 1999-09-21
HUP0000755A2 (hu) 2000-10-28
IL130839A (en) 2004-12-15
WO1998031353A1 (fr) 1998-07-23
IS5107A (is) 1999-07-06
FR2759905B1 (fr) 2001-03-09
ID21929A (id) 1999-08-12
IS2072B (is) 2005-12-15
NL1008020C2 (nl) 2000-01-18
KR100528415B1 (ko) 2005-11-15
CA2277891A1 (fr) 1998-07-23
SK96099A3 (en) 2000-01-18
FR2759905A1 (fr) 1998-08-28
ES2149083A1 (es) 2000-10-16
NL1008020A1 (nl) 1998-07-22
ATE263552T1 (de) 2004-04-15
JP2001509812A (ja) 2001-07-24
AU5786098A (en) 1998-08-07
RU2180562C2 (ru) 2002-03-20
CZ255899A3 (cs) 1999-10-13
DE69823045T2 (de) 2004-10-21
EE9900293A (et) 2000-02-15
NO993540D0 (no) 1999-07-19
SK283943B6 (sk) 2004-05-04
NO993540L (no) 1999-09-20
UA57765C2 (uk) 2003-07-15
GR980100023A (el) 1998-09-30
EE03950B1 (et) 2003-02-17
EP1014955B1 (fr) 2004-04-07
ES2217535T3 (es) 2004-11-01
PL189551B1 (pl) 2005-08-31
PL334526A1 (en) 2000-02-28
KR20000070189A (ko) 2000-11-25
DE69823045D1 (de) 2004-05-13
IL130839A0 (en) 2001-01-28
ES2149083B1 (es) 2001-05-16
BR9806893A (pt) 2000-05-16
CN1244120A (zh) 2000-02-09
AU728768B2 (en) 2001-01-18
IE980026A1 (en) 1998-10-07
EP1014955A1 (fr) 2000-07-05

Similar Documents

Publication Publication Date Title
SE9700135D0 (sv) New formulation
SE9700133D0 (sv) New formulation
SE9700134D0 (sv) New formulation
SE9700136D0 (sv) New formulation